Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) Gross Margin (2019 - 2025)

Burning Rock Biotech has reported Gross Margin over the past 7 years, most recently at 78.03% for Q4 2025.

  • For Q4 2025, Gross Margin rose 707.0% year-over-year to 78.03%; the TTM value through Dec 2025 reached 74.7%, up 443.0%, while the annual FY2025 figure was 74.67%, 442.0% up from the prior year.
  • Gross Margin for Q4 2025 was 78.03% at Burning Rock Biotech, up from 75.1% in the prior quarter.
  • Over five years, Gross Margin peaked at 78.03% in Q4 2025 and troughed at 63.13% in Q2 2022.
  • A 5-year average of 70.3% and a median of 70.93% in 2021 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: plummeted -777bps in 2022 and later surged 707bps in 2025.
  • Year by year, Gross Margin stood at 71.52% in 2021, then decreased by 0bps to 71.2% in 2022, then fell by -9bps to 64.51% in 2023, then grew by 10bps to 70.96% in 2024, then grew by 10bps to 78.03% in 2025.
  • Business Quant data shows Gross Margin for BNR at 78.03% in Q4 2025, 75.1% in Q3 2025, and 72.77% in Q2 2025.